Sorafenib Tosylate Patent Expiration
Sorafenib Tosylate is Used for treating advanced renal cell carcinoma, carcinoma of the thyroid, and unresectable hepatocellular carcinoma. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Sorafenib Tosylate Patents
Given below is the list of patents protecting Sorafenib Tosylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nexavar | US9737488 | Pharmaceutical composition for the treatment of cancer | Sep 10, 2028 | Bayer Hlthcare |
| Nexavar | US8877933 | Thermodynamically stable form of a tosylate salt | Dec 24, 2027 | Bayer Hlthcare |
| Nexavar | US8618141 | Aryl ureas with angiogenesis inhibiting activity |
Feb 11, 2023
(Expired) | Bayer Hlthcare |
| Nexavar | US7235576 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US7351834 | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US7897623 | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US8124630 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
| Nexavar | US8841330 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan 12, 2020
(Expired) | Bayer Hlthcare |
Sorafenib Tosylate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List